Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in Relapsed/Refractory Gray-Zone and Extranodal B-cell Lymphomas
NCT03255018Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2018
- Primary completion
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in gray zone lymphoma (GZL), primary central nervous system lymphoma (PCNSL), primary testicular lymphoma (PTL), primary breast lymphoma (PBL), primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), sponsored by National Cancer Institute. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
gray zone lymphoma (GZL)primary central nervous system lymphoma (PCNSL)primary testicular lymphoma (PTL)primary breast lymphoma (PBL)primary cutaneous diffuse large B-cell lymphoma (PCDLBCL)
Beyond the preview
Go deeper on NCT03255018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255018.